Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 7.4% in December

Biodesix, Inc. (NASDAQ:BDSX) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 836,600 shares, a decrease of 7.4% from the December 15th total of 903,100 shares. Based on an average daily trading volume, of 420,900 shares, the days-to-cover ratio is currently 2.0 days.

Insider Buying and Selling

In related news, Chairman John Patience bought 75,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was acquired at an average cost of $1.38 per share, with a total value of $103,500.00. Following the transaction, the chairman now directly owns 2,153,298 shares in the company, valued at approximately $2,971,551.24. This trade represents a 3.61 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew Strobeck purchased 40,000 shares of Biodesix stock in a transaction on Tuesday, November 5th. The stock was bought at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the transaction, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. The trade was a 1.56 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 315,000 shares of company stock worth $393,500 in the last ninety days. 69.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BDSX. Barclays PLC increased its position in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after acquiring an additional 21,179 shares during the last quarter. CVI Holdings LLC purchased a new stake in shares of Biodesix during the 2nd quarter valued at $59,000. Landscape Capital Management L.L.C. purchased a new position in shares of Biodesix in the 3rd quarter worth about $262,000. Perkins Capital Management Inc. grew its position in Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after buying an additional 270,724 shares during the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Trading Up 0.9 %

Biodesix stock traded up $0.01 during mid-day trading on Friday, hitting $1.15. 195,487 shares of the stock were exchanged, compared to its average volume of 222,300. The firm’s fifty day simple moving average is $1.37 and its two-hundred day simple moving average is $1.57. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix has a 12 month low of $1.09 and a 12 month high of $2.21.

Biodesix (NASDAQ:BDSX) last released its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The business had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. During the same quarter in the previous year, the business earned ($0.12) earnings per share. As a group, equities analysts predict that Biodesix will post -0.35 earnings per share for the current year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.